(ABT)

ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the ...

Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.

Live Updates Live Coverage Has Ended S&P Sinks 3% in Tech-Fueled Sell-Off 3:21 pm by Gerelyn Terzo Technology stocks are in freefall mode, sending the S&P 500 to its lows of the session for a ...

Live Updates Live Coverage Has Ended Gaines and Losers Today 12:59 pm Winners: APA Corp (APA) up 5.27% Abbott Labs (ABT) up 4.37% Devon Energy (DVN) up 4.17% Marathon Petroleum (MPC) up 3.82% Losers: ...

Abbott Laboratories NYSE: ABT is not immune to the impact of tariffs on its medical device business. However, the company's diversified business is tariff-resistant, and moves are being made to streng...

I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth...

Abbott Laboratories (NYSE:ABT ) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ET Company Participants Mike Comilla - VP, IR Robert Ford - Chairman and CEO Phil Boudreau - EVP, Finance and CF...

Abbott Laboratories (NYSE:ABT) reported a profit beat for the first quarter driven by growth in its medical devices and diabetes care segments, as revenue fell short of estimates. The healthcare compa...

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.